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1. Introduction   
The pathophysiology of severe sepsis is unique among immunological conditions in that the 
immune system is ultimately the root cause of the disease, and yet in certain aspects it is the 
immune system that suffers the most severe after effects following resolution of disease. 
During the acute phase of the disease, unchecked activation of the immune system results in 
severe physiological stress, which can lead to multi-organ dysfunction (MODS) and death 
(G. P. Patel et al., 2003). However, both during the acute phase and following recovery from 
severe sepsis, the immune system can suffer from significant deficiencies in activation and 
effector function that can render the patient susceptible to secondary, nosocomial and 
opportunistic infections (Reddy et al., 2001). This immune suppression is most readily 
apparent in regards to cellular responses, as both innate and adaptive immune cells exhibit 
deficiencies in effector responses following the onset of severe sepsis, both in vitro and in 
vivo. In certain cases, these deficiencies appear tied to the overstimulation of immune 
responses during the acute phase of the disease; for example, as macrophages become 
unresponsive to further stimulation with lipopolysaccharide (LPS) despite Gram-negative 
organisms being the (one of many possible) root cause(s) of the onset of sepsis (Fujihara et 
al., 2003). These phenomena may be considered an instance of immune tolerance as a 
consequence of overstimulation (e.g. “LPS tolerance” in macrophages both in vivo and in 
vitro). In addition, many instances of cellular dysfunction persist in survivors of severe 
sepsis long after the resolution of the acute phase of the disease; these cellular deficiencies 
are correlated in experimental models of sepsis, and play a key role in the development of 
post-septic immunosuppression. 
Cellular dysfunction following severe sepsis proceeds from the intense inflammatory 
response triggered by exposure to large quantities of microbes, microbial products, and/or 
dead and dying cells and tissues. Suppression of activation and effector function of immune 
cells can be mediated through negative regulation of signalling pathways involved in the 
sensing of microbes and dead tissues, via direct suppression of immune responses through 
the signalling activity of anti-inflammatory cytokines, and in the long term, via 
modifications to the regulation of gene expression necessary for proper activation and 
effector function of immune cells. The end result of these phenomena is an immune system 
that lacks the ability to properly mount directed inflammatory responses in the context of 
secondary infections and other pathologies (such as cancer). The observed cellular 
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dysfunction following the initial onset of sepsis can be loosely grouped into two distinct 
categories: acute deficiencies in the context of the systemic inflammatory response 
syndrome (SIRS), and chronic deficiencies in the context of the compensatory anti-
inflammatory response syndrome (CARS) and beyond (N. S. Ward et al., 2008). 
1.1 Pathophysiology of SIRS and CARS 
The initial onset of severe sepsis can be due to numerous factors, many of which are derived 
from infectious agents but are not necessarily of infectious origin. For example, LPS derived 
from Gram-negative bacterial cell walls is a potent initiator of the septic response through its 
ability to stimulate large amounts of proinflammatory cytokines through Toll-like receptor 
(TLR)-4 signalling pathways (Zhang & Ghosh, 2000). Additionally, Gram-positive cell wall 
components (e.g. lipoteichoic acid) can signal through TLR2, initiating many of the same 
proinflammatory responses as LPS stimulation (Henneke et al., 2008). Shared components of 
both Gram-negative and –positive bacteria are the presence of unmethylated CpG motifs 
within the bacterial genome; these CpG motifs can be sensed by TLR9 (Wagner, 2002). 
Several types of RNA species, especially double-stranded RNA (dsRNA) from viruses, and 
intracellular RNA released from necrotic host cells (Cavassani et al., 2008), can activate TLR3 
(Sen & Sarkar, 2005) as well as intracellular dsRNA sensors such as RIG-I and MDA-5 
(Takeuchi & Akira, 2008). Additionally, bacterial superantigens (SAgs) can activate 
peripheral T cells in a non-specific, polyclonal manner, leading to the undirected production 
of proinflammatory cytokines and the development of sepsis (Ferry et al., 2005; Fraser & 
Proft, 2008). Despite the disparity in the instigating agent(s), the pathophysiology of the 
disease follows a biphasic progression, based on the generalized immune responses to the 
original stimuli and the subsequent “cytokine storm,” respectively. 
The systemic inflammatory response syndrome (SIRS) is defined clinically as the presence of 
two of the following four symptoms: hyper/hypothermia, tachycardia, tachypnea and 
leukocytosis/leukopenia with exaggerated neutrophils (>10% of peripheral white blood 
cells) (Conference:, 1992). From an immunological perspective, SIRS is a result of the 
exaggerated production of proinflammatory chemokines and cytokines by large numbers of 
activated immune cells. For example, early inflammatory mediators such as Tumor Necrosis 
Factor-alpha (TNFα), Interleukin-1 beta (IL-1ȕ), IL-6 and IL-8 (CXCL8) are responsible for 
the variation in body temperature, breathing rate and peripheral white blood cell count, and 
the overproduction of these mediators can result in further exacerbation of inflammatory 
responses as well as immune cell apoptosis (Unsinger, McDonough, et al., 2009). 
Overproduction of proinflammatory chemokines and cytokines by the innate immune 
system (e.g. macrophages, granulocytes and dendritic cells) can feed back on the adaptive 
immune system, resulting in amplification of SIRS through production of type I (Kelly-
Scumpia et al., 2010) and type II interferons (IFN) (Romero et al., 2010; Silva & Cohen, 1992) 
and T-cell derived cytokines such as IL-17(Flierl et al., 2008). The “cytokine storm” of SIRS is 
multifaceted, and reflects the multiple possible instigating agents and the multiple immune 
cell types participating in the response.  
The cytokine storm of SIRS results in morbidity and mortality through the stresses caused 
by the unchecked inflammation on the host’s physiology. For example, SIRS results in a 
massive apoptotic/necrotic cell death event observable in primary and secondary lymphoid 
tissues, as well as in the peripheral blood (Wesche-Soldato et al., 2005). This widespread cell 
death has two major outcomes. First, by significantly reducing the number of available 
leukocytes, this cytokine-storm induced cell death leaves the patient susceptible to 
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secondary infections (C. Oberholzer et al., 2001). Secondly, cell components released by 
dying cells (especially nucleic acids and mitochondrial proteins) can further amplify the 
cytokine storm through stimulation of TLRs on remaining immune cells – this is especially 
true in the case of necrosis (Cavassani et al., 2008). Extreme variations in body temperature, 
heart rate and breathing rate are also mediated by the unchecked production of 
proinflammatory chemokines and cytokines (Sriskandan & Altmann, 2008). Ultimately, 
these physiological stresses, combined with adverse coagulation events and damage to the 
vasculature, can result in SIRS-induced mortality. 
The initiation of SIRS is ultimately a result of immune cell activation; as a result, the immune 
system will often attempt to overcompensate for the overproduction of proinflammatory 
chemokines and cytokines by upregulating anti-inflammatory mediators. These anti-
inflammatory mediators can be immunosuppressive cytokines, such as IL-10 or 
transforming growth factor-beta (TGFȕ), or immune-deviating cytokines, such as T-helper 
type 2 cytokines (such as IL-4 and IL-13) which attempt to counteract the largely T-helper 
type 1 response initiated by SIRS cytokines (such as IL-12 and IFNȖ) (Adib-Conquy & 
Cavaillon, 2009). Unfortunately, these compensatory mechanisms often fail to restrict the 
damaging effects of the cytokine storm of SIRS; instead, they often render those leukocytes 
that survive the initial apoptotic/necrotic event unable to respond to further infectious 
stimuli. This is especially dangerous at timepoints proximal to the onset of severe sepsis, as 
it renders hospitalized patients (undergoing treatment for SIRS) at risk for developing 
nonsocomial infections. Recent epidemiological studies also suggest that the CARS response 
may persist in some form for days, months and years following the resolution of severe 
sepsis and discharge from hospital care, as the both the survival rates and quality of life of 
survivors of severe sepsis are significantly reduced when compared to the healthy age-
matched population (Perl et al., 1995; Quartin et al., 1997).  
Cellular immune dysfunction as a result of severe sepsis can therefore be further 
conceptualized as three distinct phases, all following the initial onset of SIRS due to 
overstimulation of the immune system. In the first phase, anti-microbial responses are 
blunted due to “exhaustion” of the inflammatory responses of cells responding to the septic 
insult. In the second phase, the upregulation of anti-inflammatory responses by the immune 
system, in an attempt to regulate SIRS, renders the immune system unable to deal with 
secondary infections; this can be thought of as early-phase CARS, or compensatory 
immunosuppression. In the third phase, immune cells that have survived severe sepsis 
retain deficiencies in activation and effector function even after the resolution of disease; this 
can be thought of as late-phase CARS or post-septic immunosuppression. These last two 
phases occur as a direct response to cytokine storm of CARS, and are defined loosely based 
on their proximity to the initiation of severe sepsis.  In all three cases, the phenotypic 
responses of the human patient or animal model (susceptibility to secondary, nosocomial 
and opportunistic infections) follows in part from the inability of the cells of the immune 
system to properly respond to challenges following sepsis. The specific mechanisms 
underlying the immunoparalysis observed in survivors of severe sepsis are specific to both 
the cell type and the phase of disease progression, but all ultimately deal with deficiencies in 
the activation, differentiation and effector function of post-septic immune cells.  
1.2 Immune dysfunction in sepsis – clinical and experimental outcomes 
Epidemiologically, immune suppression following sepsis manifests as a significant decrease 
in the long-term survival of patients recovered from severe sepsis; this decrease is seen years 
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after the resolution of the inflammatory episode, as compared to the healthy age-matched 
population. Additionally, patients who do survive severe sepsis report lower quality of life 
scores as compared to healthy control populations (Winters et al., 2010). Of the patients that 
succumb to increased morbidity and mortality following sepsis, there are numerous 
infectious and non-infectious comorbidities that are correlated with decreased life 
expectancy. For example, opportunistic infections are commonly associated with patients 
recovering from septic shock (Benjamim et al., 2004). The long-term decrease in life 
expectancy observed in patients post-sepsis is described in epidemiological studies, and the 
underlying etiology of this post-septic mortality is less clear; however, the increase in 
mortality observed in post-septic patients appears unreleated to associated comorbidities, 
and is a direct result of the severity of the initial septic episode (Quartin et al., 1997). 
Experimentally, post-septic immunosuppression can be studied by utilizing “two-hit” 
models of disease, whereby experimental animals are subjected to severe sepsis and then 
challenged with a secondary infection or immunity-stimulating event (such as solid tumor 
challenge). These models have been critical for both the identification of long term 
immunosuppression in survivors of severe sepsis, as well as for discerning the underlying 
mechanisms of cellular immune dysfunction following sepsis. Classical “two-hit” models 
often utilize a sepsis-triggering effect (such as high dose LPS injection or surgical induction 
of sepsis, also known as cecal ligation and puncture, CLP) in combination with airway 
challenges with opportunistic micro-organisms. The use of the lung microenvironment to 
study secondary infections and post-septic immunosuppression is of particular importance. 
By utilizing secondary infections that originate in the lung, researchers can study the 
immune environment in the lung during sepsis, where immune responses can both initiate 
septic shock and exacerbate deleterious outcomes (such as in the case of acute respiratory 
distress syndrome) (Hudson et al., 1995). 
Experimental models of “two-hit” post-septic immunosuppression often utilize 
opportunistic pathogens for the second challenge, as healthy animals (untreated, or 
subjected to sham surgery as a control) would be expected to clear the microorganism 
without difficulty. One classic example of such an opportunistic pathogen is the fungi 
Aspergillus fumigatus, whose infectious conidia are ubiquitous in the environment and are 
normally controlled by a fully functioning immune system (Walsh et al., 2005). In 
immunocompromised individuals, these condidia can germinate in the lung and result in 
invasive infection. In mice, A. fumigatus airway challenge results in little discernible 
pathology, with the conidia unable to germinate prior to clearance by innate immune cells 
with phagocytotic activity (such as macrophages and neutrophils). In contrast, mice that 
have recovered from severe sepsis are unable to generate protective immune responses to A 
fumigatus conidia; these animals ultimately succumb to invasive aspergillosis, characterized 
by tissue damage mediated by hyphal outgrowth in the lungs (Benjamim et al., 2003). 
Deficiencies in cellular immune responses in post-septic animals are directly responsible for 
the susceptibility of post-septic animals to A. fumigatus-induced mortality. In addition to 
fungal challenge, other microorganisms are utilized to study post-septic 
immunosuppression in murine models. Secondary bacterial challenges are especially useful 
for modelling nosocomial infections in human patients; susceptibility to secondary 
infections has been identified in mouse models using Pseudomonas aeruginosa or Listeria 
monocytogenes, among others (Delano et al., 2011). Post-septic animals are also more 
susceptible to the implantation of solid tumors, as tumor size is increased in post-septic 
animals as compared to controls(Cavassani et al., 2010).  
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Impaired immune cell function plays a key role in mediating post-septic 
immunosuppression in all the experimental models discussed previously. In addition, these 
same deficiencies in immune cell function underlie the susceptibility of human patients to 
secondary, nosocomial and opportunistic infections following the onset of severe sepsis. Cell 
populations within the innate and adaptive immune system exhibit distinct phenotypes that 
mediate the different phases of post-septic immunosuppression, and the interplay between 
these various celluar deficiencies results in the susceptibility to infection observed in both 
human patients and animal models.  
2. Immune cell dysfunction during SIRS  
Despite immune activation being the root cause of severe sepsis, the cytokine storm 
associated with acute inflammation also feeds back on peripheral immune cells to mediate 
immunosuppression. This immunosuppression is mediated through two general 
mechanisms. First, widespread apoptosis of peripheral leukocytes limits the population of 
immune cells (and immune cell progenitors) available to respond to secondary infections. 
Second, overstimulation of surviving leukocytes - due to exposure to large amounts of 
microbial products, apoptotic/necrotic cell products and/or chemokines & cytokines – 
results in a refractory response to secondary stimulation, as is the case with a concurrent 
nosocomial infection during severe sepsis. The combination of these two factors results in 
susceptibility to secondary infections proximal to the onset of sepsis. In human patients, this 
response manifests as nosocomial infections that present soon after the admittance of the 
patient to emergency/intensive care; in animal models, this early immunosuppression is 
modelled with secondary infections early after the onset of sepsis (24-72 hours following 
induction). 
The physiological stress caused by the cytokine storm of sepsis results in a widespread 
apoptotic event, coupled with (and amplified by) the necrosis of damaged tissues and 
subsequent release of intracellular components (e.g. proteins and nucleic acids). This 
apoptotic event is mediated both cell-contact dependent (such as Fas-Fas ligand 
interactions) and cell contact-independent mechanisms (Mahidhara & Billiar, 2000). In 
regards to cell contact-independent mechanisms, instead of a single causative event, the 
combined stress of the multiple chemokines and cytokines upregulated by severe sepsis 
combine to induce apoptosis in multiple immune cell types. In addition, adverse 
coagulation events caused by unchecked activation of the complement cascade can also 
induce immune cell death, especially in the vasculature and susceptible immune organs 
(such as the bone marrow and spleen) (P. A. Ward, 2008). Within a relatively short time 
following the onset of sepsis – hours to days – primary and secondary lymphoid organs are 
significantly depleted of cells as a result of this apoptosis. For example, cell density is 
significantly reduced in the bone marrow, thymus and spleen during acute sepsis; this is 
especially striking in the thymus, where the organ shrinks in size dramatically during the 
early inflammatory response of severe sepsis (Riedemann et al., 2002; Wang et al., 1994). In 
addition, peripheral tissue-resident immune cells, such as dendritic cells (DCs), decrease in 
number during the acute phase of sepsis, in part due to cytokine storm-induced cell 
death(Tinsley et al., 2003). 
The widespread immune cell apoptosis significantly limits the number of cells available to 
combat a secondary infection. Complicating this response is the limited activation potential 
of immune cells that survive the initial apoptotic event. As mentioned previously, severe 
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sepsis is induced through widespread activation of pattern recognition receptors (such as 
TLRs) and/or indiscriminate activation of nominally antigen-specific pathways (such as the 
case with polyclonal activation of T cells with superantigen). As a result of this excessive 
stimulation, the surviving immune cells become refractory to further stimulation through 
these specific pathways – this results in blunted responses to microbes and microbial 
products, leading to impaired immunity to secondary infections. This phenomenon is 
particularly evident in phagocytic cells of the innate immune system, manifested as a 
reduction in proinflammatory responses to secondary exposure to microbial products. 
In macrophages, for example, prolonged exposure to high doses of LPS, as can be seen 
during severe sepsis, can result in refractory responses to further TLR signalling (Biswas & 
Lopez-Collazo, 2009). This suppressed TLR-mediated response is evidenced by a reduction 
in proinflammatory chemokine and cytokine production (Fujihara et al., 2003), as well as 
modulations in costimulatory ligand expression (Newton et al., 2004). This response is 
particularly prevalent in sepsis cases with a predominantly Gram-negative etiology, and 
high-dose LPS exposure in experimental models either in vivo or in vitro is often used to 
mimic this suppressed response (Medvedev et al., 2006). The phenomenon of “LPS 
tolerance” is intimately linked with the level of LPS exposure, as relatively low amounts 
(approximately 1 ng/ml in in vitro experiments) of LPS pre-treatment can enhance rather 
than suppress subsequent proinflammatory responses (West & Koons, 2008). However, high 
doses of LPS can result in suppressed extracellular signal-regulated kinase activity during 
subsequent secondary LPS exposures, including mitogen-activated protein kinases (MAPKs) 
and c-Jun NH2-terminal kinase (JNK), with subsequent decreases in NF-κB and AP-1 
transcription factor activity (Adib-Conquy et al., 2000; Fan & Cook, 2004; West et al., 2007). 
This decrease in TLR4-mediated signal transduction can lead to decreased production of 
proinflammatory genes such as Tumor Necrosis Factor-alpha (TNFα), interleukin(IL)-1ȕ and 
IL-12, among others (Munoz et al., 1991; Spolarics et al., 2003).  
Prolonged exposure to microbial products (and LPS in particular) also has a deleterious 
effect on the proinflammatory responses of neutrophils, although this response is distinct 
from the phenotype of “LPS tolerized” macrophages. Neutrophils play a critical role in 
initiating the septic response, as the early activation of neutrophils can lead to organ and 
tissue damage through the overproduction of reactive oxygen species (ROS) and highly 
active proteases such as neutrophil elastase (Fujimi et al., 2002; Sabroe et al., 2005). 
Additionally, accumulation of neutrophils in the vasculature and peripheral organs can 
result in non-specific cell and tissue damage, further complicating sepsis-induced organ 
dysfunction (Brown et al., 2006). Paradoxically, however, decreased neutrophil function 
during acute phase sepsis (characterized by decreased chemotactic responses and impaired 
surface receptor expression) is correlated with decreased survival in human patients, 
suggesting that the suppression of the antimicrobial functions of neutrophils is not enough 
to protect against sepsis-induced mortality (Chishti et al., 2004; Muller Kobold et al., 2000). 
Importantly, neutrophils are critical for the clearance of many nosocomial infections, as well 
as central to the innate immune responses against many experimental models of “two-hit” 
post-septic immunosuppression. Exhaustion of neutrophil functions during the acute phase 
of sepsis can therefore lead to susceptibility to secondary infections. For example, 
neutrophils that survive the early apoptotic event exhibit decreased chemotactic responses 
to neutrophil chemoattractants, most notably via CXCR1, which mediates neutrophil 
responses to CXCL8/IL-8 (Duffy et al., 2000). This reduced sensitivity to CXCL8 is similar to 
reduced TLR4 signalling in septic macrophages, as surface levels of CXCR1 are not reduced 
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on septic neutrophils; rather, the ability of CXCR1 to signal through G-protein coupled 
receptor (GPCR) signalling pathways appears impaired (Arraes et al., 2006; Reddy et al., 
2008). Therefore, in a similar fashion to “LPS tolerized” macrophages, septic neutrophils are 
impaired in their ability to respond to secondary microbial stimuli, leaving the septic patient 
susceptible to secondary infections. 
In addition, a form of passive immune suppression can be seen during early phase sepsis in 
the increase in immature neutrophils – also known as “band cells” or “banded neutrophils” 
– in peripheral blood and immune organs of patients and animal models. Banded 
neutrophils are immature neutrophils that have differentiated from granulocyte/monocyte 
precursors in the bone marrow, but have yet to fully differentiate into mature neutrophils 
(Klut et al., 1998). Increases in peripheral banded neutrophils have long been used as a 
simple diagnostic tool for inflammatory responses; while their use as a predictive tool for 
sepsis severity (and subsequent mortality) is under question, their presence as a result of 
severe inflammatory responses is well characterized (Cavallazzi et al., 2010; Cornbleet, 2002; 
M. J. Ward et al., 2010). The increase in peripheral banded neutrophils appears to be a 
response of the bone marrow to the widespread apoptosis of mature neutrophils in response 
to the cytokine storm of sepsis – however, while the newly released neutrophils are rapidly 
produced, they lack many of the functional aspects of fully differentiated neutrophils (Pillay 
et al., 2010). The increased number of banded neutrophils therefore may arise at the loss of 
fully differentiated and functional neutrophils. Just as the loss of leukocytes due to 
apoptosis renders septic patients and animal models susceptible to secondary infections, the 
increase of banded neutrophils can contribute to post-septic immunosuppression, as these 
cells are not able to control secondary infections in the same manner as mature, functional 
neutrophils.  
It may appear paradoxical to identify cellular immune suppression in the context of 
uncontrolled inflammation, particularly in the population of peripheral innate immune cells 
(such as macrophages and neutrophils) that are largely responsible for the cytokine storm of 
severe sepsis. It is therefore important to consider that the peripheral innate immune 
compartment during the acute phase of sepsis is a heterogeneous mixture of pro-
inflammatory cells, “exhausted” cells (as mentioned previously) and in addition, cells which 
have converted to a regulatory or suppressive phenotype in an attempt to counteract the 
uncontrolled inflammatory response. In the hours and days proximal to the onset of severe 
sepsis, this combination of immune cell phenotypes results in the multifaceted disease 
phenotype of sepsis, whereby uncontrolled inflammation both results in tissue damage and 
mortality, and renders bystander immune cells unable to respond to secondary infections. 
3. Immune cell dysfunction during CARS and beyond 
Despite the immunosuppressive phenomena discussed previously (LPS tolerance, 
chemokine desensitization, etc), the acute phase of sepsis is primarily defined by the over 
activation of proinflammatory mechanisms, in particular cytokine and chemokine 
production by activated immune cells. The widespread immune cell apoptosis and anergy 
(unresponsiveness to immunogenic stimuli) often fails to completely control the cytokine 
storm of sepsis; as a compensatory mechanism, the immune system attempts to switch to 
active mechanisms of immune suppression, in an attempt to resolve the SIRS response. 
These active mechanisms, including the production of anti-inflammatory cytokines and the 
generation, activation and differentiation of suppressor cells, are considered hallmarks of 
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the compensatory anti-inflammatory response syndrome (CARS) (A. Oberholzer et al., 
2001). Classically, the CARS response was considered to be the generalized switch from pro- 
to anti-inflammatory cytokines during the acute phase of sepsis; this is evidenced by 
increased production of suppressive cytokines (such as IL-10) and cytokines which 
counteract the primarily TH1-type inflammation of severe sepsis (such as TH2 type cytokines 
IL-4, -5 and -13) (Miller et al., 2007). Recent epidemiological studies in human patients, along 
with studies of experimental animal models of sepsis, have identified the CARS response as 
being maintained in immune cells for extended timepoints, long after the resolution of 
sepsis. These responses still retain components of early-phase CARS, such as the TH2 
cytokine shift, but are also characterized by cell-intrinsic defects in activation, differentiation 
and effector function that blunt the effectiveness of post-septic immune cells to protect the 
host from opportunistic infections. In this conception, CARS can be defined as a 
multifaceted immunosuppression following the onset of severe sepsis that leaves the patient 
susceptible to increased morbidity and mortality as compared to healthy individuals. In a 
generalized categorization, early-phase CARS can be described in terms of directed immune 
cell suppression via cytokine and the directed activity of suppressor cells, while late-phase 
CARS can be described as cell-intrinsic defects in activation, differentiation and effector 
function. 
3.1 Early phase CARS: Suppressor cells and immunosuppressive cytokines 
The switch from SIRS to CARS represents a directed effort by the immune system to 
regulate the production of proinflammatory chemokines and cytokines that are mediating 
physiological stress and tissue damage. When considering the cellular mediators of SIRS, 
such as innate immune cells (e.g. macrophages and neutrophils), cell-extrinsic suppression 
of their effector function can proceed through cell contact-dependent and –independent 
mechanisms. In terms of cell contact-dependent mechanisms, the development and 
expansion of myeloid and lymphoid suppressor cells is one of the hallmarks of CARS, and 
the persistent presence of these cells can restrict cellular immune responses to secondary 
infections. In terms of cell contact-independent mechanisms, the production of suppressive 
cytokines (e.g. IL-10), cytokine-sequestering factors (e.g. soluble TNF receptor type II) and 
immune-deviating cytokines (e.g. IL-4 and IL-13) all serve to restrict immune responses to 
secondary infections as well. One important hallmark of these early phase responses is their 
direct correlation with the uncontrolled cytokine storm of SIRS; these early phase CARS 
responses are directly triggered by the proinflammatory cascade of acute sepsis, and may 
represent a final effort by the immune system to restrict the cytokine- and chemokine-driven 
inflammation of SIRS.  
The development and expansion of suppressor cells during CARS is multifaceted, and 
encompasses both myeloid-derived and lymphoid-derived suppressor cells. In certain cases, 
the expansion of suppressor cells is due to the directed development of cells with 
suppressive phenotypes from bone marrow progenitor cells; this is postulated to be the case 
with the heterogeneous population of myeloid-derived suppressor cells (MDSCs) seen in the 
periphery of survivors of severe sepsis (Cuenca et al., 2011). In other cases, the relative 
expansion of cells with suppressive phenotypes is thought to be due to the deletion of 
effector cells during SIRS due to cytokine driven apoptosis; this is often described with the 
increase in peripheral regulatory T cells (Tregs) following sepsis (Venet et al., 2004). In either 
case, the resulting suppressor cells are defined by their ability to directly regulate the 
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activation of immune cells, including suppression of antigen presentation by accessory 
myeloid cells such as DCs, and restriction of the antigen-specific proliferation and effector 
function of T lymphocytes. The development of suppressor cells is a compensatory 
mechanism by the host to restrict the widespread inflammation of SIRS, both through 
biasing the peripheral immune cell pool towards cells with suppressive phenotypes, as well 
as utilizing those suppressive cells to directly regulate those proinflammatory cells that have 
failed to restrict their own activation through previously discussed mechansims (e.g. 
tolerance induction, apoptosis, etc).  
Much of what is understood about MDSCs in humans comes from studies in cancer 
patients, where studies of peripheral blood leukocytes have identified a heterogeneous 
population of cells with stem cell markers on their surface (i.e. CD34) (Marigo et al., 2008). 
These cells are heterogeneous, both in terms of surface marker expression and in 
morphology, consisting of both monocyte and granulocyte subtypes. As a heterogeneous 
population, MDSCs have the ability to suppress the immune responses of other leukocytes, 
most notably T cells; co-cultures of MDSCs with CD4+ T cells result in decreased cell surface 
marker expression and cytokine production in response to antigen stimulation (Lechner et 
al., 2010). Their presence in the context of cancer is thought to arise through the modulatory 
activity of the malignancy, in an attempt to shield the growing tumor from immune 
surveillance (in a similar fashion as the development of tumor-associated macrophages) 
(Mantovani et al., 2009). In animal models of sepsis, MDSCs appear in peripheral immune 
organs in the days following experimental onset of the disease; these cells mimic the human 
MDSCs in their heterogenicity, their mixed monocyte and granulocyte morphology, and 
their ability to suppress antigen-specific lymphocyte responses in vitro (Delano et al., 2007).  
While there remains a paucity of data concerning direct observation of MDSCs in human 
patients during severe sepsis and following recovery, techniques have been developed to 
generate MDSCs from peripheral blood mononuclear cells, utilizing a cocktail of cytokines 
that are also key players in the cytokine storm of severe sepsis (such as IL-6, IL-1ȕ and TNF-
α) (Lechner et al., 2010). The majority of experimental data concerning MDSCs in sepsis 
comes from experimental models, especially in the mouse – peripheral MDSCs can be 
induced by high dose LPS treatment, and these cells exhibit multifaceted 
immunosuppressive capabilities, including suppression of antigen-specific responses 
(Bronte, 2009; De Wilde et al., 2009). The source of peripheral MDSCs appears to be from 
progenitor cells in the bone marrow, although their presence as a terminally differentiated 
cell population vs. a mobilized population of immature leukocytes in response to 
inflammation and subsequent peripheral cell apoptosis (often referred to as “emergency 
myelopoiesis”) remains in question. In addition, their role as mediators of post-septic 
immunosuppression is unclear, both due to the paucity of MDSC data from human septic 
patients, and in the difficulty inherent in eliminating MDSCs from the periphery of 
experimental animals. This difficulty arises from the lack of a definitive marker for MDSCs, 
in particular one that is not shared by other immune cells (e.g. macrophages and 
neutrophils). For example, many published studies in animal models utilize anti-Gr1 
antibodies to deplete peripheral MDSCs to study their impact on disease (Nausch et al., 
2008; Ribechini et al., 2009); however, this antibody also depletes mature neutrophils, and 
anti-Gr1 treatment on its own can render mice susceptible to opportunistic infections due to 
the depletion of these neutrophils (Mehrad et al., 1999). However, the correlative data from 
human patients, in context with the studies in animal models of sepsis, suggest that severe 
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sepsis can result in an increase in peripheral MDSCs. When coupled with their ability to 
suppress antigen-specific activation and effector function of lymphocytes, MDSCs become a 
strong candidate for mediating post-septic immunosuppression. 
In addition to myeloid-based suppressive cells, restriction of immune cell function post-
sepsis is mediated by suppressive lymphoid cells as well. Arguably the best understood of 
these suppressive lymphocytes is the CD4+ regulatory T cell (Treg). Tregs are themselves 
relatively heterogeneous, based on cell surface marker phenotype, tissue of residence, 
and/or the disease (or disease model) where the cells are studied. While Tregs are nominally 
defined by their suppressive activity (both in vivo and in vitro), they are identified by the 
expression of the transcription factor Foxp3 (Campbell & Ziegler, 2007), and are correlated 
with the expression of specific cell surface markers (most notably CD25, but also CTLA-4 
and GITR, among others) (Wilczynski et al., 2008). Tregs have the capacity to suppress 
antigen-specific responses by effector T cells, as well as inflammatory responses by innate 
immune cells (Suzuki et al., 2010). Tregs are critical for the maintenance of peripheral 
immune tolerance, and deletion of Tregs in animal models results in the development of 
autoimmunity (Suri-Payer & Fritzsching, 2006). In humans, genetic mutations in the Foxp3 
gene results in the development of autoimmune disease (i.e. IPEX syndrome), due to a 
breakdown of Treg-mediated suppression of self-antigen responses in the periphery (van der 
Vliet & Nieuwenhuis, 2007). Additionally, accumulations of Tregs in peripheral organs can 
help suppress immune responses and promote tolerance induction; examples of this 
phenomenon include inflammatory bowel disorders (Uhlig et al., 2006), allergic asthma (W. 
F. Carson et al., 2008) and transplant tolerance (Ge et al., 2010). In a negative context, 
peripheral Tregs can also suppress tumor surveillance by the adaptive immune system, 
indicating that in certain disease contexts, Tregs can promote rather than reduce pathology 
(Nishikawa & Sakaguchi, 2010).  
Phenotypic analysis of peripheral blood from patients suffering from severe sepsis indicates 
an increase in CD4+ Tregs (Venet et al., 2009). This increase is seen rapidly following the onset 
of disease, and can persist throughout recovery (defined as the resolution of the cytokine 
storm), especially in animal models of sepsis. The origin of the increased Tregs is 
controversial, as certain studies describe the increase as being a directed expansion of Tregs 
and others as a result of the depletion of effector T cells due to sepsis-induced apoptosis 
(Venet et al., 2004; Wisnoski et al., 2007). Interestingly, in vivo studies utilizing PBMCs 
indicate that bacterial SAgs have the capacity to induce Foxp3 expression, suggesting that 
certain types of polyclonal stimuli associated with severe sepsis can directly modulate Treg 
numbers (Taylor & Llewelyn, 2010).  Regardless of the nature of this increase, however, it is 
clear that peripheral Tregs are enhanced in number in post-septic patients. At present, 
experimental modulation in Tregs has focused on their role in mediating the severity of acute 
sepsis; however, recent studies have begun to shed light on the role of Tregs in mediating 
post-septic immunosuppression. For example, increases in peripheral Treg numbers in 
humans correlates with the development of suppressive phenotypes in peripheral 
lymphocytes from the same patients (Monneret et al., 2003). In animal models of sepsis, ex 
vivo blockade of Foxp3 via treatment with silencing RNAs (siRNA) can restore the 
proliferative responses of splenocytes, suggesting that Foxp3-dependent mechanisms are 
mediating lymphocyte anergy in post-septic animals (Venet et al., 2009). The direct effect of 
peripheral Tregs in mediating post-septic immunosuppression remains unclear; however, 
similar experimental models of secondary infections following trauma suggest an important 
role for Tregs in mediating immunosuppression following uncontrolled inflammation. For 
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example, in animal models of severe burn injury, secondary infection with Pseudomonas 
aeruginosa results in increased mortality as compared to healthy control mice. Importantly, 
experimental neutralization of Treg in vivo in these animals reverses this susceptibility (Liu et 
al., 2011).  
Of particular interest to the study of post-septic immunosuppression is the nature of Treg 
generation. Functional Tregs can be generated in two distinct pathways; either in the thymus 
(“natural” Tregs) or in the periphery in response to antigen stimulation in the context of 
tolerance-promoting signals, such as immunosuppressive cytokines (“adaptive” or 
“induced” Tregs) (Bluestone & Abbas, 2003). As mentioned previously, one possible 
explanation for the observed increase in peripheral Tregs following sepsis is the concurrent 
apoptosis of effector T cells; this would suggest that it is natural Tregs that are the primary 
regulatory T cell type following sepsis. However, studies of peripheral CD4+ T cells in 
animal models of sepsis suggest that following the onset of inflammation, peripheral 
effector T cells may have an increased propensity to become Tregs in response to secondary 
stimulus, due to modulations in their gene regulation patterns (Cavassani et al., 2010). This 
suggests that severe sepsis may condition the peripheral T cell pool to respond in a more 
regulatory fashion to secondary antigen challenges, which would ultimately result in an 
increase in immune suppression at the cost of protective pro-inflammatory responses. These 
modulated gene regulatory events will be discussed in the following sections dealing with 
late-phase CARS, as similar gene regulatory events underlie cell-intrinsic defects in the 
activation and effector function of other leukocytes during long-term sepsis-induced 
immunosuppression. 
In concert with the increase in suppressive immune cells, imbalances in cytokine production 
by the immune system during the switch from SIRS to CARS can also contribute to post-
septic immunosuppression. Characterization of the upregulation of these soluble mediators 
comes from studies at the physiological level, i.e. analysis of peripheral blood samples from 
human patients or peripheral tissues from animal models. The relative increase in these 
soluble anti-inflammatory mediators is observed in survivors of severe sepsis, and the 
presence of these mediators has a profound effect on the ability of leukocytes to respond to 
secondary infections. Soluble mediators of post-septic immunosuppression can be grouped 
into three general categories based on their mechanism of action: anti-inflammatory 
cytokines, soluble cytokine-sequestering receptors and immune-deviating cytokines. While 
the ultimate function of each grouping is different (i.e. direct suppression vs. immune-
deviating), all three types of soluble factors contribute to post-septic immunosuppression. 
The most well understood of the many immunosuppressive cytokines produced during 
CARS is arguably IL-10 (Bazzoni et al., 2010). Signalling via IL-10 proceeds through a 
heterodimeric receptor (IL-10R1/IL-10R2 complex), and the intracellular signalling 
pathways associated with IL-10 receptor activation (including involvement of tyrosine 
kinases and the transcription factor STAT3) have the ability to directly regulate cytokine 
gene expression induced by LPS; this makes IL-10 an intriguing candidate for mediating 
post-septic immunosuppression, especially in regards to LPS-dependent secondary 
responses (Crepaldi et al., 2001). Supporting this concept is the kinetics of IL-10 expression 
in human patients and animal models, where increased levels of IL-10 can be observed 
following the onset of sepsis (van der Poll et al., 1997). Blockade of IL-10 has been shown to 
have a protective effect in many experimental models of severe sepsis (Latifi et al., 2002; 
Oberholzer et al., 2002). Interestingly, however, increased IL-10 production in human 
patients is often correlated with poor outcomes, suggesting that IL-10 may be a potent 
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regulator of the CARS response (Abe et al., 2008). IL-10 has potent suppressive effects on a 
wide range of leukocytes, including suppression of proliferation, surface receptor expression 
and cytokine/chemokine production (Akdis & Blaser, 2001; Williams et al., 2004). Of particular 
interest is IL-10’s potent effect on monocytes and macrophages, primarily mediated by the 
antagonistic effect of IL-10 signalling on LPS-dependent gene induction (Cavaillon & Adib-
Conquy, 2006). IL-10 has dramatic suppressive effects on the pro-inflammatory responses of 
macrophages, including inhibition of cytokine production (Brandtzaeg et al., 1996; Gerard et 
al., 1993). IL-10 can also negatively impact neutrophil activation in the context of LPS 
stimulation (as seen with Gram-negative sepsis), as neutrophils only expresses the IL-10R 
following LPS stimulation; in this fashion, IL-10 serves as a negative regulator of activated 
neutrophils (Cassatella et al., 2005; Tamassia et al., 2008). In a normal physiological context, 
limited by either the kinetics of stimulation or the restricted microenvironment of a given 
inflammatory insult, the IL-10-dependent negative feedback look allows the immune system 
to properly regulate the potentially damaging anti-inflammatory effects of macrophages and 
neutrophils following the clearance of infectious micro-organisms. However, the high levels of 
IL-10 produced during CARS can drastically shift the balance away from pro-inflammatory 
responses, leaving peripheral macrophages and neutrophils unable to respond to secondary 
bacterial challenges unrelated to the causative agent of septic shock.  
In addition to IL-10, the shift from SIRS to CARS is also associated with an increase in 
transforming growth factor-beta (TGFȕ). TGFȕ is a potent cytokine that is normally involved 
with wound healing and the development of fibrosis in damaged tissues (Leask & Abraham, 
2004). TGFȕ also has the ability to direct the activation and differentiation of many cell 
types, including but not limited to immune cells. In the context of immune responses, TGFȕ 
is a potent immunosuppressive cytokine, with the ability to suppress the antigen-specific 
activation and effector function of leukocytes (Prud'homme & Piccirillo, 2000). Additionally, 
TGFȕ signalling in the context of T-cell receptor signalling can direct the development of 
CD4+ Tregs from effector T cell precursors (Li & Flavell, 2008). In the context of severe sepsis, 
TGFȕ is significantly increased in the systemic circulation (Marie et al., 1996); this increase is 
both due to the directed production of TGFȕ by immune cells, but also as a byproduct of 
sepsis-induced apoptosis, as TGFȕ is produced by apoptotic cells (T cells in particular) 
during programmed cell death (Chen et al., 2001). TGFȕ isoforms (of which there are 3 
primary forms) signal through cell surface receptors through SMAD transcription factors, 
which regulate numerous genes, including those responsible for mediating apoptosis (for 
example, through downregulation of anti-apoptotic genes such as Bcl-xl) (Kanamaru et al., 
2002; Spender et al., 2009). TGFȕ signalling can also limit chemokine and cytokine 
production by immune cells, in particular T lymphocytes and activated macrophages 
(Letterio, 2005; Yang et al., 2010). In particular, TGFȕ is a potent suppressor of the anti-
microbial activity of macrophages; this is manifest via TGFȕ-mediated suppression of 
cytotoxic activity, superoxide production and nitric oxide synthase (iNOS) activity (Mitra & 
Khar, 2004). This increase in TGFȕ during sepsis can therefore suppress secondary anti-
microbial responses by macrophages, limiting the ability of these cells to respond to 
secondary infections. In addition, as TGFȕ signalling is important for the differentiation of 
effector CD4+ T cells into Tregs, there appears to be a role for increased TGFȕ production 
post-sepsis in mediating the increase in peripheral Tregs observed in human patients and 
animal models. Therefore, in addition to TGFȕ’s direct immunosuppressive properties (as 
with IL-10), TGFȕ can also mediate immunosuppression through the development of cells 
with intrinsic immunosuppressive properties. 
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The immunosuppression observed during early phase CARS proceeds both through the 
production of anti-inflammatory cytokines, but also through the production of soluble 
factors that can limit the ability of pro-inflammatory cytokines to signal cells and mediate 
inflammation. Of particular importance to the switch from SIRS to CARS is the production 
of soluble receptors and antagonists that interfere with the signalling of the 
proinflammatory cytokines IL-1ȕ, IL-6 and TNFα. All three cytokines are central mediators 
of SIRS through their ability to drive the acute phase response, fever, cytotoxic activity of 
immune cells (e.g. phagocytosis) and ultimately septic shock (Jean-Baptiste, 2007). As a 
result, during the switch from SIRS to CARS, the immune system upregulates the 
production of cytokine antagonists which attempt to block the activity of these 
inflammatory mediators. For example, in septic patients, plasma levels of soluble IL-1ra 
receptor antagonist (IL-1ra), soluble TNFα receptors I and II (sTNFRI/sTNFRII), and soluble 
IL-6 receptor (sIL-6R) are all increased as compared to healthy patients (Gogos et al., 2000; 
Marie et al., 1997). IL-1ra binds the IL-1 receptor in competition with IL-1ȕ, resulting in 
functional inhibition of IL-1ȕ signalling (Bresnihan & Cunnane, 1998). In a similar fashion, 
the sTNFRs and sIL-6R achieve functional inhibition of their respective cytokines by binding 
and sequestering the soluble proteins from interacting with cell surface receptors on 
circulating leukocytes (Jones & Rose-John, 2002). As with the upregulation of anti-
inflammatory cytokines, the production of receptor antagonists and soluble receptors is an 
attempt by the immune system to restrict the cytokine storm of SIRS. However, blockade of 
the functional activity of these cytokines can result in vulnerability to secondary infections, 
especially when placed in context with the upregulation of anti-inflammatory cytokines 
such as IL-10 and TGFȕ.  
For cellular immune responses to be protective, they must be conditioned to produce the 
proper inflammatory response for the specific infectious agent. The cytokine storm of SIRS 
can be loosely categorized as a T helper type-1 response (TH1), geared towards cytotoxic 
activity and anti-microbial responses. Many cytokines central to sepsis responses, such as 
TNFα, IL-6, IL-12 and IFNȖ, are normally considered to be TH1-type cytokines, as they 
promote the cytotoxic activity of macrophages, neutrophils and CD8+ cytotoxic T cells. T-
helper type-2 responses (TH2) are associated with immunity to parasites, as well as allergic 
responses, and are characterized by antibody production (primarily immunoglobulin type 
E) and eosinophilopoiesis (at the expense of neutrophils). TH2 cytokines have the ability to 
directly regulate TH1 responses through their ability to suppress TH1 gene expression in 
CD4+ T cells, as well as by modulating the granulocyte output of the bone marrow in 
response to inflammation (i.e. eosinophils vs. neutrophils) Summaries of the T-helper 
cytokine response and its role in inflammation are available in the literature (Cameron et al., 
2001; DiPiro, 1997; Miller et al., 2007). As a third cytokine-dependent mechanism, the 
cytokine milleu of CARS is also characterized by an upregulation of TH2 cytokine responses 
(Mack et al., 1996). This upregulation of TH2 cytokines serves to blunt the TH1-dominant 
SIRS response through the modulation of leukocyte gene expression. In human patients, 
immune responses post-sepsis are observed to have a generalized shift towards TH2 
responses, especially in regards to adaptive immune cell activation (O'Sullivan et al., 1995). 
IL-4 in particular has potent effects on macrophages, with the ability to suppress cytotoxic 
activity as well as promote the production of IL-1ra and sTNFRs, resulting in an autocrine 
feedback loop that further restricts macrophage activity (Nicod et al., 1994). In addition, TH2 
cytokines like IL-4 and IL-13 are key factors in the development of alternatively activated 
macrophages (aaMΦ, or M2-type macrophages), which promote wound healing and fibrosis 
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at the expense of anti-microbial activity (Gordon & Martinez, 2010). Animal models of sepsis 
have identified that bone-marrow derived macrophages from survivors of sepsis exhibit a 
M2 phenotype as compared to control animals, suggesting that the TH2 cytokine-dependent 
development of M2 macrophages can be maintained for timepoints distal from the acute 
inflammatory event (Takahashi et al., 2004).  
Because a majority of the studies dealing with soluble mediators of the CARS phenotype are 
done on the physiological level (i.e. with analysis of peripheral blood samples), it is often 
difficult to directly identify the source of the immunomodulatory cytokines mediating 
CARS. In the case of soluble receptors and receptor antagonists, the root source is often 
considered to be macrophages and other phagocytotic innate immune cells, especially in 
response to circulating IL-10 levels. As mentioned previously, increases in TGFȕ production 
are often the result of lymphocyte apoptosis during sepsis; however, many T cells, especially 
Tregs, can produce both TGFȕ and IL-10 when mediating immunosuppression. Many of the 
TH2 cytokines observed during CARS are normally produced by CD4+ T cells, and it is 
hypothesized that these cells are at the root of the TH12 shift observed in survivors of severe 
sepsis. Conceptually, the shift from SIRS to CARS may result from a negative feedback loop 
whereby the proinflammatory cytokine storm results in the apoptosis of cells, resulting in 
increased TGFȕ production that then leads to the development of Tregs that produce IL-10, 
which then go on to stimulate anti-inflammatory responses (i.e. IL-1ra, sTNFR & sIL-6R) 
from macrophages, and so on. This type of model may explain the mechanisms underlying 
the switch from SIRS to CARS; however, they do not fully explain the maintenance of post-
septic immunosuppression in patients for the months and years following recovery. 
Investigations into the long-term maintenance of the CARS phenotype have identified many 
cell-intrinsic defects in activation and effector function that maintain the immunsuppressive 
phenotype once the relative levels of anti-inflammatory cytokines and antagonistic factors 
have returned to baseline levels in the periphery. It is hypothesized that these cell-intrinsic 
factors may be programmed by the cytokine milleu of either SIRS or CARS; additionally, 
they may utilize modulation in gene regulation as an underlying mechanism for the 
maintenance of these defects. 
3.2 Late phase CARS: Cellular dysfunction and epigenetic reprogramming 
Sepsis-induced immunosuppression during SIRS and the early switch to CARS relies on 
active mechanisms, such as cytokine-induced apoptosis, anergy induction, suppression of 
signal transduction and modulation of bone marrow hematopoiesis. Ultimately, however, 
these mechanisms of suppression resolve as the patient recovers from the septic episode. For 
example, despite the widespread apoptosis & necrosis of immune cells observed during the 
acute phase of sepsis, immune cells are ultimately re-seeded into immune tissues and 
peripheral blood & lymph following recovery. Interestingly, the re-seeding of T 
lymphocytes to peripheral organs does not appear to favor specific T cell-receptor subtypes 
(Unsinger, Kazama, et al., 2009). This phenomenon suggests that the repopulation of 
lymphocytes is not due simply to the expansion of cells primed during the acute phase of 
septic shock. However, despite the return of the immune system to a state comparable to 
conditions pre-sepsis, both human patients and experimental animals continue to exhibit 
signs of immunosuppression. As mentioned previously, the long term survival curves of 
survivors of severe sepsis are significantly reduced as compared to the healthy age-matched 
population, and this increased morbidity and mortality is observable even in the presence of 
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co-morbidities. Additionally, self-reported quality of life measurements are significantly 
reduced in survivors of severe sepsis, indicating negative physiological outcomes even in 
the absence of secondary infection. Taken in context, these results suggest that the cellular 
immune response in post-septic individuals remains dysregulated even once the major 
mediators of CARS have subsided.  
Experimental studies aimed at identifying cell-intrinsic defects in activation and effector 
function of immune cells following severe sepsis have described numerous 
immunosuppressive phenomena that are maintained even after the resolution of SIRS and 
CARS. These deficiencies in activation and effector function are considered to be cell-
intrinsic as they manifest both in vivo and in vitro, are often preserved in adoptive transfer 
models, and are in many cases resistant to treatment with optimized culture conditions (e.g. 
polyclonal stimulus and exogenous recombinant cytokines). In “two-hit” models of post-
septic immunosuppression, these cell-intrinsic defects contribute directly to the 
susceptibility of survivors of severe sepsis to opportunistic infections, as adoptive transfer of 
immune cells from control animals can confer protect in these immunosuppressed animals. 
The current working hypothesis for this phenomenon deals with gene regulation in post-
septic cells, in particular with the expression of proinflammatory cytokines that are 
necessary for protection against secondary infection. In this model, immune cells that have 
survived septic shock are no longer able to effectively respond to secondary infectious 
stimuli due to the repression of gene expression following activation. While many disparate 
yet interrelated molecular mechanisms may be involved in this dysregulation of gene 
expression, recent studies have implicated epigenetic reprogramming of immune cells (and 
possibly hematopoietic progenitor cells) as a major player in long-term immunosuppression 
post-sepsis (W. F. Carson et al., 2011). 
Perhaps the most well-characterized immune cell deficiency following sepsis is concerning 
the activation of DCs. As mentioned previously, DCs are rapidly depleted from peripheral 
tissues following the onset of sepsis, and as DCs are critical for the antigen-specific 
activation of T cells, this loss of peripheral DCs severely restricts the activation potential of 
the adaptive immune system (Tinsley et al., 2003). Interestingly, peripheral DCs that do 
return following the resolution of SIRS and early-phase CARS continue to exhibit an 
immunosuppressive phenotype following sepsis, highlighted by a significant reduction in 
their ability to produce IL-12 in response to TLR stimulation (Wen et al., 2006). IL-12 is a 
potent pro-inflammatory cytokine that is critical for the development of TH1 responses and 
TH1-type CD4+ T cells (Watford et al., 2003). This inability to produce IL-12 results in 
susceptibility to pathogens that are normally cleared by a TH1 immune response. 
Experimentally, this response can be studied using airway challenges with Aspergillus 
fumigatus in post-septic mice – the reduction in DC-dependent IL-12 production in these 
animals restricts the development of TH1 responses, resulting in uncontrolled fungal growth 
and Aspergillus-induced mortality (Benjamim et al., 2003). When bone-marrow derived DCs 
from control animals are transferred into post-septic animals prior to airway challenge, 
resistance to fungal infection can be restored (Benjamim et al., 2005). Interestingly, this 
suppression of IL-12 production does not appear to be due to increased IL-10 production; 
while ex vivo stimulated post-septic DCs exhibit increased IL-10 production (an expected 
CARS-type cytokine response), neutralization of IL-10 in vitro with blocking antibodies fails 
to restore IL-12 production (Wen, Dou, et al., 2008). Importantly, this suppression of IL-12 
production is maintained long past the resolution of severe sepsis, with lung DCs exhibiting 
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deficiencies in IL-12 production up to six weeks following the experimental onset of sepsis 
(Wen, Dou, et al., 2008). From a therapeutic standpoint, this long-term suppression of IL-12 
production is problematic, as it does not follow from the upregulation of anti-inflammatory 
cytokines that can themselves be blocked (as with in vitro inhibition of IL-10).  
DCs are critical accessory cells for the activation of T cells, through the presentation of 
antigen to T-cell receptors in the context of MHC. In addition, DCs instruct T cells to 
differentiate into one of several effector/regulatory cell lineages (characterized by distinct 
families of effector cytokines and downstream immunomodulatory functions); this 
instruction occurs both through cell-contact dependent mechanisms and the production of 
instructional cytokines (such as IL-12). As mentioned previously, post-septic immune 
responses are characterized by a generalized shift away from TH1 cytokines towards TH2 
cytokines. This phenomenon may be due at least in part to the immunomodulatory 
properties of post-septic DCs, as these cells promote TH2 cytokines such as IL-4, IL-5 and IL-
13 at the expense of TH1 cytokines such as IFNȖ (Wen et al., 2006). This skewing to TH2 occurs 
in an antigen-specific fashion, and is not a result of pre-conditioning of the responder T cells 
during severe sepsis, as the responder cells used in these in vitro experiments were naïve 
and specific for an antigen that is unrelated to polymicrobial sepsis (ovalbumin). This 
reduction in TH1 polarizing capabilities may also negatively regulate innate immune system 
functions, as TH1 CD4+ T cell-derived IFNȖ is critical for the activation of phagocytotic 
activity by macrophages (Kasten et al., 2010).  
In addition to DC-mediated suppression, CD4+ T cell exhibit deficiencies in activation, 
differentiation and effector function following sepsis, even in the context of polyclonal 
stimulus or nominally functioning DCs. One of the hallmarks of CD4+ T cells from septic 
patients is the development of anergy, or unresponsives to antigen stimulation (Heidecke et 
al., 1999). CD4+ T cells from septic animals also exhibit this anergic phenotype, and the 
proliferative capacity of these cells is not recovered by the addition of exogenous cytokines, 
such as the potent T cell proliferative factor IL-2 (W. F.  Carson et al., 2010). In addition, their 
gene expression is drastically altered as compared to CD4+ T cells from healthy animals. For 
example, mRNA for IFNȖ, IL-4 and the TH17 cytokine IL-17 can be upregulated in naïve 
CD4+ T cells from post-septic mice following polyclonal stimulus, as compared to levels in 
cells from control animals. Concurrently, these cells downregulate mRNA for cell surface 
receptors critical for T cell activation, including CD4 and CD28. As these differences in gene 
expression are observed following optimized polyclonal stimulus in the absence of 
accessory cells such as DCs, it appears that the changes in gene expression are due to cell-
intrinsic factors (W. F.  Carson et al., 2010). 
This modulated cytokine response by post-septic CD4+ T cells becomes even more apparent 
once these cells are tasked with committing to specific T-helper lineages. When studied in 
vitro, post-septic CD4+ T cells exhibit deficiencies in their ability to properly commit to 
either the TH1 or TH2 lineage, as evidenced by cytokine production. For example, when 
expanded in an optimized TH1-promoting environment (including exogenous IL-12 and 
blocking antibodies to IL-4), post-septic CD4+ T cells produce significantly less IFNȖ in 
recall responses, as compared to CD4+ T cells from control animals. If these same cells are 
expanded in a TH2 culture (exogenous IL-4 and blocking antibodies to IL-12 and IFNȖ), post-
septic CD4+ T cells produce both TH1 and TH2 cytokines upon recall, whereas CD4+ T cells 
from control animals only make TH2 cytokines (W. F.  Carson et al., 2010). This modulation 
in T-helper subtype cytokine responses represents an inability of post-septic CD4+ T cells to 
properly commit to either the TH1 or TH2 effector lineage.  
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This modulated cytokine production is also apparent in vivo, when post-septic CD4+ T cells 
are transferred into lymphopenic animals (i.e. Rag2-/- mice, which lack mature peripheral 
lymphocytes). As mentioned previously, post-septic myeloid cells exhibit numerous 
deficiencies in activation and cytokine production throughout SIRS, early and late phase 
CARS; as these cells are critical for the activation of CD4+ T cells, any deficiencies observed 
in lymphocyte activation in vivo in post-septic animals may be due to myeloid deficiencies, 
and not necessarily due to CD4+ cell-intrinsic factors. Adoptive transfer experiments allow 
post-septic CD4+ T cells to be studied in the context of a functional myeloid immune cell 
response, as both macrophages and DCs develop and function normally in (genetically 
engineered) lymphopenic mice. When post-septic CD4+ T cells are challenged with in vivo 
models of TH1 or TH2 lung inflammation, a similar pattern of cytokine expression emerges. 
Histological examination of lung granuloma formation in response to embolized antigen-
coupled beads indicates that post-septic CD4+ T cells mediate smaller TH1 and TH2 type 
lesions, as expected based on the generalized shift to TH2 responses following sepsis (W. F.  
Carson et al., 2011). Interestingly, when lymph nodes from mice that received post-septic 
CD4+ T cells were restimulated with cognate antigen, they produced increased amounts of a 
wide range of T-helper cytokines, including IL-4 in a TH1 context, and IFNȖ in TH2 context. 
Additionally, in both TH1 and TH2 disease models, lymph nodes from mice that received 
post-septic CD4+ T cells produced increased IL-17 as compared to those that received CD4+ 
T cells from control mice. In both cases, this inability to properly commit to a T-helper 
lineage results in measurable differences in both in vivo inflammatory processes and ex vivo 
cytokine production (W. F.  Carson et al., 2011). While it may be counter-intuitive to suggest 
that increased pro-inflammatory cytokine production is indicative of immunosuppression, it 
is important to place this increase in the context of productive inflammation. Adaptive 
immunity requires directed cytokine production to initiate proper immune responses 
directed against the specific infectious agent (i.e. TH1 responses for intracellular bacterial 
and viral infections vs. TH2 responses for helminth infections). Increases in T-helper 
cytokines can be counterproductive when they promote incorrect inflammatory responses 
(as seen with the TH1 granuloma studies) or exacerbate inflammation past the level of 
protection (as seen with the TH2 granulomas). When coupled with the shift towards TH2 
responses observed with DCs post-sepsis, this dysregulation of cytokine expression can 
ultimately result in decreased immunity to secondary infections, which normally require 
TH1 responses for clearance. 
During late phase CARS, both myeloid cells (specifically DCs) and lymphoid cells 
(specifically CD4+ T cells) exhibit deficiencies in cytokine production in response to 
stimulation with microbes, microbial products and antigens. As mentioned previously, 
following the apoptotic response during SIRS, both DCs and CD4+ T cells are re-seeded to 
the periphery, in many cases to levels similar to those found in control animals or healthy 
individuals. These results suggest that the mechanisms governing cytokine responses in 
post-septic cells are both cell-intrinsic and not reliant on exogenous factors, such as soluble 
mediators of early phase CARS (e.g. IL-10, IL-1ra, etc). Recent studies in animal models have 
identified one possible molecular pathway governing this dysregulation of gene expression 
and cytokine production, epigenetics. The study of epigenetics involves any and all 
molecular mechanisms that can modulate gene expression without changing the underlying 
genetic information present in a cell or organism. Epigenetic mechanisms include chemical 
modifications to DNA and DNA-associated histone proteins that can either activate or 
suppress gene transcription, as well as expression of small RNA species (called 
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microRNAs/miRNAs) that can post-transcriptionally regulate gene expression through the 
targeted degradation of mRNA (Delcuve et al., 2009). Epigenetics plays a critical role during 
embryogenesis and development, particularly when multipotent stem cells commit to 
defined lineages during the development of tissues and organs (Roloff & Nuber, 2005; Shafa 
et al., 2010). The differentiation process requires tight regulation of gene expression, as the 
differentiation of stem cells into cells with defined phenotypes requires not only the 
activation of essential genes, but also the suppression of genes unrelated to the function of 
the new daughter cell. In a similar fashion, the immune system relies on epigenetic 
mechanisms to guide the development of peripheral blood leukocytes from hematopoietic 
cell precursors (Bergman & Cedar, 2010; Fernandez-Morera et al., 2010). In addition, the 
activation, differentiation and effector function of peripheral immune cells also relies on 
epigenetic mechanisms. For example, modifications in the tails of histones associated with 
the promoter regions of essential gene families correlates with the decision of macrophages 
to become either classically activated (i.e. anti-microbial) or alternatively activated (i.e. 
fibrotic/wound healing) (Ishii et al., 2009). In addition, CD4+ T cells utilize similar histone 
modification processes to govern the expression of T-helper cytokines during the 
differentiation to TH1 or TH2 (Ansel et al., 2003). When these processes are disrupted in 
immune cells, disease can often result; for example, modulations in DNA methylation 
patterns (DNA methylation results in the suppression of gene expression) are often 
correlated with the development of systemic lupus erythematosus (D. R. Patel & 
Richardson, 2010). Regulation of gene expression is essential for the proper function of the 
immune system, and changes in the epigenetic landscape of an immune cell can have a 
profound effect on immune responses and subsequent disease. 
Recent studies in animal models have identified a number of epigenetic modifications in 
immune cells following severe sepsis. These modifications are often found associated with 
genes essential for immune cell effector function, such as cytokine genes or transcription 
factors, and they correlate with deficiencies in activation, differentiation and effector 
function in these cells. Additionally, these modifications are found in both myeloid and 
lymphoid cells, suggesting a common molecular mechanism for the modification of 
epigenetic marks in leukocytes following sepsis. At present, the best described epigenetic 
mechanism governing post-septic immunosuppression is via histone modification events, in 
particular changes in histone acetylation and methylation. Post-translational modifications 
of the protein tails of histone core proteins can have a direct effect on gene expression, 
depending on the type of modification and its location on the histone tail (Cosgrove & 
Wolberger, 2005). For example, acetylation of histone tails is often associated with 
transcriptional activation, regardless of the location of the modification on the histone tail. In 
contrast, the functional result of the methylation of histone tails is site specific; 
transcriptional activation or repression can occur depending on the location of the 
methylation event on the histone tail. Studies of both myeloid and lymphoid cells post-
sepsis have identified modulations in both histone acetylation and methylation following 
sepsis, in particular in the promoter regions of genes essential for mediating protective 
immune responses against secondary infections. 
In DCs, for example, modulations in histone methylation events in the promoter regions of 
IL-12 are observable following sepsis (Wen, Schaller, et al., 2008). When tissue-resident DCs 
from post-septic animals are compared to those from healthy controls, the pattern of histone 
methylation is skewed towards gene repression. This includes decreases in methylation of 
lysine 4 on the tail of histone 3 (H3K4me), which is considered an activating epigenetic 
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mark, as well as increases in methylation of lysine 27 on the tail of histone 3 (H3K27me), 
which is considered a repressive epigenetic mark. These marks are maintained for a 
significant amount of time following the resolution of severe sepsis, as tissue-resident DCs 
from post-septic animals retain these modulated methylation marks six weeks after the 
experimental onset of severe sepsis. In addition, the chromatin modifying enzymes 
responsible for the addition of these histone methylation marks is significantly altered in 
post-septic DCs, with the H3K4me machinery decreased and the H3K27me machinery 
increased in the promoter regions of both IL-12a and IL-12b . This increase in repressive 
histone methylation marks correlates with decreased IL-12 production both in vitro and in 
vivo, and provides one explanation for the observed reduction in proinflammatory cytokine 
production that is unrelated to the presence of anti-inflammatory cytokines (i.e. IL-10) (Wen, 
Dou, et al., 2008). 
While the data concerning epigenetic reprogramming in macrophages is less robust in 
regards to long-term immunosuppression, modulations in histone modifications can be 
observed in macrophages following the onset of severe sepsis, and these modulations affect 
proinflammatory responses by these cells. For example, macrophages recovered from 
experimental models of severe sepsis exhibit increased levels of methylation at lysine 9 of 
histone 3 (H3K9, repressive) at the promoter region of both IL-1ȕ and TNFα, resulting in 
decreased production of both inflammatory mediators (Lyn-Kew et al., 2010). This increase 
in repressive histone methylation appears to be a mechanism whereby the immune system 
is attempting to limit proinflammatory cytokine production; however, as both of these 
cytokines are critical for immunity against bacteria, their decreased production by 
macrophages can leave the immune system less able to properly respond to secondary 
infections. In addition, decreases in H3K4me and increases in acetylation of the tail of 
histone 4 (AcH4) are observed both in the TNFα and iNOS promoter; reductions in iNOS 
expression severely limit the ability of the macrophage to produce nitric oxide, a critical 
component of the cytotoxic response. To date, few studies have been performed to 
determine if these aberrant histone modification events remain present in macrophages long 
after the resolution of SIRS. However, recent studies identifying an epigenetic role for the 
development of the alternatively activated macrophage (decreases in H3K27 methylation 
mediated by the histone demethylase KDM6B) may provide a mechanism for the increased 
propensity of post-septic macrophages to become alternatively activated, as the increase in 
KDM6B expression and activation is driven by TH2 cytokines that are upregulated during 
CARS, most notably IL-4 (Ishii et al., 2009).  
Epigenetic reprogramming of CD4+ T cells following sepsis is also apparent, both in regards 
to cytokine production and T-helper lineage commitment. As mentioned previously, CD4+ 
T cells from post-septic animals exhibit deficiencies in their ability to properly commit to 
either the TH1 or TH2 lineage, as evidenced by modulations in cytokine production during 
recall/re-challenge both in vivo and in vitro. These deficiencies in lineage commitment 
correlate with modulations in histone modifications, specifically increases in H3K27me 
levels in promoter regions of T-helper subtype genes. For example, post-septic CD4+ T cells 
exhibit increased levels of H3K27me in the promoter region of Ifng, correlating with the 
decreased production of IFNȖ during skewing and restimulation experiments in vitro. In 
addition, these same cells exhibit increased levels of H3K27me in the promoter region of 
Gata3, a transcription factor critical for the development of TH2 T cells. This increase in 
repressive histone methylation correlates with the reduced capacity of post-septic T cells to 
fully commit to the TH2 lineage, as evidenced by the continued production of IFNȖ in TH2 
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inflammatory contexts both in vitro and in vivo (W. F.  Carson et al., 2010; W. F.  Carson et al., 
2011). In addition to modulations in histone methylation, histone acetylation is also 
modulated in post-septic CD4+ T cells, in particular the CD4+ CD25- T cell subset that is 
thought to consist primarily of effector cells. CD4+ CD25- T cells from post-septic animals 
exhibit increases in H3K9 acetylation (H3K9ac) in the promoter region of Foxp3 (Cavassani 
et al., 2010); Foxp3 is a transcription factor considered to be a master regulator of Treg 
function, and expression of Foxp3 is essential for the suppressive activity of Tregs. In 
addition, CD4+ CD25- T cells from post-septic mice exhibit increased expression of Kat2a 
mRNA; Kat2a is the chromatin modifying enzyme responsible for the addition of the 
H3K9ac mark. The concurrent increase in both H3K9ac and Kat2a in post-septic CD4+ T 
cells correlates with the increase in both Treg numbers and functional activity in post-septic 
mice; in terms of post-septic immunosuppression, this increase in Treg results in increased 
susceptibility to solid tumor challenge. Taken together, these studies indicate that following 
severe sepsis, CD4+ T cells exhibit modulations in the epigenetic regulation of gene 
expression, via changes in histone modifications, and that these changes can have significant 
effects on the activation, differentiation and effector function of these cells at timepoints 
post-sepsis.  
Clearly, post-septic immunosuppression is a chronic condition, and can manifest itself in 
survivors of severe sepsis long after the resolution of SIRS and CARS-associated cytokine, 
chemokine and soluble mediator production. Of particular importance is the ability of post-
septic immunosuppression to manifest itself even after the resolution of active suppressive 
mechanisms, such as with the increase in peripheral IL-10 and TGFȕ observed during CARS. 
Studies of leukocyte function in experimental models of severe sepsis have identified 
numerous activation deficiencies in post-septic cells, centred on dysregulated cytokine and 
transcription factor expression. One possible explanation of the maintenance of this 
immunosuppressive phenotype is via changes in gene expression due to modulations in the 
epigenetic signatures of post-septic leukocytes. However, these studies have up to now been 
limited in scope, even within the field of epigenetics, as there remains many other epigenetic 
mechanisms (such as histone phosphorylation, DNA methylation, miRNA expression, etc) 
that may also be playing a role in mediating post-septic immunosuppression. In addition, 
much work remains to be done in correlating the gene regulatory events observed during 
late-phase CARS in animals with the phenotypes of peripheral blood leukocytes in patients 
who have recovered from severe sepsis. However, studies in animal models provide 
experimental data to bolster the findings from epidemiological studies in humans – namely, 
that post-septic immunosuppression can last far beyond the resolution of CARS, and the 
long-term survival of severe sepsis patients can be adversely effected by the improper 
function of the post-septic immune system.  
4. Conclusion  
Following the onset of severe sepsis, the cellular immune system is tasked with responding 
to both the septic insult, and any subsequent secondary infections or challenges, while also 
balancing the need to restrict the same pro-inflammatory responses that are mediating 
sepsis-induced mortality. The initial molecular mechanisms intended to resolve sepsis-
induced mortality – namely, the increase in anti-inflammatory and immune-deviating 
cytokines observed during CARS – can render the cellular immune system unable to 
respond to secondary infections. In addition, apoptosis of immune cells during SIRS may 
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remove those cells from participating in the cytokine storm of severe sepsis, but it reduces 
the number of functional immune cells able to respond to opportunistic and nosocomial 
infections. Following recovery from sepsis, the cellular immune system retains many 
deficiencies in activation and effector function, resulting in persistent immunosuppression 
that can adversely affect the long-term survival of patients who have recovered from severe 
sepsis. Ultimately, the cellular immune system is faced with a seemingly unsolvable 
paradox, in that limiting cellular activation can protect the organism from sepsis-induced 
mortality, only to leave the door open for mortality based on secondary infections during 
recovery. 
Despite what is known about the nature of cellular immunosuppression following severe 
sepsis, many questions still remain to be answered. Of particular importance is the apparent 
link between the severity of the septic response (i.e. the cytokine storm) and the 
development of post-septic immunosuppression. It appears that the severity of the septic 
response, presumably as measured by the qualitative severity of the cytokine storm, is 
directly related to the development of post-septic immunosuppression. However, it is not 
clearly understood whether the development of immunosuppression is due to the increased 
level of a specific cytokine, or due to the combined presence of multiple proinflammatory 
cytokines acting in concert. Clearly, neutralization of individual cytokines during SIRS (for 
example, by utilizing mice that are genetically deficient) can have a dramatic effect on the 
sepsis-induced mortality; however, it remains to be seen whether the resulting effects on 
post-septic immunosuppression are due to the neutralization of the specific 
proinflammatory cytokine or a generalized effect of reducing the severity of the septic 
shock. In addition, much work remains to be done on the role of the cytokine storm of SIRS 
in modulating long-term immunosuppression, in particular the setting of epigenetic marks 
in post-septic leukocytes. It remains to be seen if the setting of specific epigenetic marks – 
along with the up- or down-regulation of chromatin modifying enzymes – is mechanistically 
driven by the cytokine milleu during SIRS.  
From a clinical perspective, the persistence of post-septic immunosuppression presents a 
challenge for both diagnosis and treatment. Treatments aimed at reducing the severity of the 
acute phase of severe sepsis may help reduce sepsis-induced mortality at the expense of 
exacerbating CARS-associated mortality. Modulation of epigenetic mechanisms may prove 
useful for restoring immune function post-sepsis, but the available pharmacological 
approaches against histone modifications are limited. In addition, the diagnostic tools 
available to diagnose post-septic immunosuppression remain few, as not all survivors of 
severe sepsis go on to develop immunosuppressive phenotypes. To date, there are few 
described markers useful for the diagnosis of post-septic immunosuppression, aside from 
either functional analysis of peripheral blood leukocytes or, unfortunately, the development 
of secondary, opportunistic or nosocomial infections in the patient. Ultimately, these 
challenges associated with the proper diagnosis and treatment of post-septic 
immunosuppression makes this phenomenon a significant human health concern. 
In summary, immune cell dysfunction is an important sequela of severe sepsis. This 
dysfunction manifests in three distinct phases following the onset of disease: during SIRS as 
a result of cell apoptosis and exhaustion, during the switch from SIRS to CARS as a result of 
directed immunosuppression by cells and soluble factors, and for the long term (CARS and 
beyond) due to cell-intrinsic defects in activation, differentiation and effector function. As a 
result, survivors of severe sepsis remain susceptible to secondary infections long after 
recovery from the acute phase of the inflammatory response. Despite the current 
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understanding of the mechanisms governing post-septic immunosuppression, much 
remains to be understood concerning the development of this phenomenon and the proper 
treatments and therapies to recover the proper function of the immune system in post-septic 
patients.  
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